Tumour mutation score is a better predictor than TMB

Home > Oncology > WCLC 2019

Read the full Report (pdf)

World Conference on Lung Cancer

07–10 September 2019 Barcelona, Spain

Featured articles

Letter from the Editor

Editor

Dr Stefan Rauh, Centre Hospitalier Emile Mayrisch, Esch

Conference

WCLC 2019

8 November, 2019 23:30

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By

Prof. Scott Gettinger, Yale Cancer Center, USA

Trial

CheckMate 017, CheckMate 057

Conference

WCLC 2019

8 November, 2019 23:00

Online First

Screening, Detection, and Diagnosis

Tumour mutation score is a better predictor than TMB

Conference

WCLC 2019

8 November, 2019 23:42

New technologies in lung cancer detection

Conference

WCLC 2019

8 November, 2019 22:50

Non-Small-Cell Lung Cancer

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Presented By

Prof. Scott Gettinger, Yale Cancer Center, USA

Trial

CheckMate 017, CheckMate 057

Conference

WCLC 2019

8 November, 2019 23:00

Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

Trial

KEYNOTE-021, KEYNOTE-189, KEYNOTE 407

Conference

WCLC 2019

8 November, 2019 22:57

pTMB is a feasible predictive biomarker for chemoimmunotherapy

Conference

WCLC 2019

8 November, 2019 21:58

Promising phase 1 results of novel KRAS-inhibitor in NSCLC

Presented By

Dr Ramaswamy Govindan, Washington University School of Medicine, USA

Conference

WCLC 2019

8 November, 2019 20:59

Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer

Presented By

Dr Alexander Drilon, Memorial Sloan Kettering Cancer Center, USA

Trial

LIBRETTO-001

Conference

WCLC 2019

8 November, 2019 19:01

High need for biomarkers for stage III lung cancer

Conference

WCLC 2019

8 November, 2019 18:03

CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days

Conference

WCLC 2019

8 November, 2019 17:05

Other Thoracic Malignancies

Durvalumab added to etoposide improves outcomes in ES-SCLC

Trial

CASPIAN

Conference

WCLC 2019

8 November, 2019 23:06

Talazoparib + low-dose temozolomide seems promising in ES-SCLC

Conference

WCLC 2019

8 November, 2019 22:08

New targets in thymic epithelial tumours may aid in identifying treatment options

Conference

WCLC 2019

8 November, 2019 21:10

Novel targets in mesothelioma may aid in developing treatment strategies

Trial

Phase 2, ADAM

Conference

WCLC 2019

8 November, 2019 09:11

Immuno-Oncology

BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors

Conference

WCLC 2019

8 November, 2019 23:14

Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities

Presented By

Dr Fabrice Barlesi, Hôpitaux de Marseille, France

Trial

Phase 4, CHECKMATE-817

Conference

WCLC 2019

8 November, 2019 21:15

Tackling immunotherapy resistance

Conference

WCLC 2019

8 November, 2019 09:17

Targeted Therapy

Older age and low neutrophilia inflammation predictor for osimertinib efficacy

Conference

WCLC 2019

8 November, 2019 23:19

EGFR TKI retreatment effective after earlier discontinuation

Conference

WCLC 2019

8 November, 2019 09:20

Phase 3 Trial Updates

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Presented By

Dr Martin Reck, Lung Clinic Grosshansdorf, Germany

Trial

KEYNOTE-024

Conference

WCLC 2019

8 November, 2019 23:23

Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC

Trial

Phase 3, IMpower 131

Conference

WCLC 2019

8 November, 2019 21:25

Less focus on quality of life in recent phase 3 trials

Conference

WCLC 2019

8 November, 2019 09:26

Medical Conferences

WCLC 2019

Featured articles

Letter from the Editor

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

CONTENTS

Online First

Screening, Detection, and Diagnosis

Tumour mutation score is a better predictor than TMB

New technologies in lung cancer detection

Non-Small-Cell Lung Cancer

Five-fold increase of OS at 5 years with nivolumab vs docetaxel

Pembrolizumab + chemotherapy beneficial in advanced NSCLC, even without PD-L1 expression

pTMB is a feasible predictive biomarker for chemoimmunotherapy

Promising phase 1 results of novel KRAS-inhibitor in NSCLC

Selpercatinib (LOXO-292) shows durable activity in RET fusion-positive lung cancer

High need for biomarkers for stage III lung cancer

CAR T cell therapy in lung adenocarcinoma may be beneficial, but still early days

Other Thoracic Malignancies

Durvalumab added to etoposide improves outcomes in ES-SCLC

Talazoparib + low-dose temozolomide seems promising in ES-SCLC

New targets in thymic epithelial tumours may aid in identifying treatment options

Novel targets in mesothelioma may aid in developing treatment strategies

Immuno-Oncology

BMI and age do not influence survival/irAEs in patients treated with immune checkpoint inhibitors

Nivolumab + ipilimumab safe first-line treatment for NSCLC patients with comorbidities

Tackling immunotherapy resistance

Targeted Therapy

Older age and low neutrophilia inflammation predictor for osimertinib efficacy

EGFR TKI retreatment effective after earlier discontinuation

Phase 3 Trial Updates

First-line pembrolizumab monotherapy offers durable OS benefit vs chemotherapy in NSCLC patients with high PD-L1 expression

Longer OS with atezolizumab + carboplatin + nab-paclitaxel in advanced squamous NSCLC

Less focus on quality of life in recent phase 3 trials